Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Dyslipidemia in obesity: mechanisms and potential targets.

Klop B, Elte JW, Cabezas MC.

Nutrients. 2013 Apr 12;5(4):1218-40. doi: 10.3390/nu5041218. Review.

2.

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Review.

3.

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Nov 14;11:140. doi: 10.1186/1475-2840-11-140. Review.

4.

[Diabetic dyslipidaemia and the atherosclerosis].

Márk L, Dani G.

Orv Hetil. 2016 May 8;157(19):746-52. doi: 10.1556/650.2016.30441. Review. Hungarian.

PMID:
27133274
5.

New insights into the pathophysiology of dyslipidemia in type 2 diabetes.

Taskinen MR, Borén J.

Atherosclerosis. 2015 Apr;239(2):483-95. doi: 10.1016/j.atherosclerosis.2015.01.039. Epub 2015 Feb 7. Review.

PMID:
25706066
6.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
7.

Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease.

Holvoet P.

Verh K Acad Geneeskd Belg. 2008;70(3):193-219. Review.

PMID:
18669160
8.

Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives.

Chapman MJ.

Atherosclerosis. 2003 Nov;171(1):1-13. Review.

PMID:
14642400
9.

Metabolic syndrome update.

Grundy SM.

Trends Cardiovasc Med. 2016 May;26(4):364-73. doi: 10.1016/j.tcm.2015.10.004. Epub 2015 Oct 31. Review.

PMID:
26654259
10.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
11.

Treatment of lipid disorders in obesity.

Tonstad S, Després JP.

Expert Rev Cardiovasc Ther. 2011 Aug;9(8):1069-80. doi: 10.1586/erc.11.83. Review.

PMID:
21878051
12.

The metabolic basis of atherogenic dyslipidemia.

Vinik AI.

Clin Cornerstone. 2005;7(2-3):27-35. Review.

PMID:
16473258
13.

Effect of GLP-1 based therapies on diabetic dyslipidemia.

Patel VJ, Joharapurkar AA, Shah GB, Jain MR.

Curr Diabetes Rev. 2014;10(4):238-50. Review.

PMID:
24998439
14.

Catabolism of lipoproteins and metabolic syndrome.

Therond P.

Curr Opin Clin Nutr Metab Care. 2009 Jul;12(4):366-71. doi: 10.1097/MCO.0b013e32832c5a12. Review.

PMID:
19474714
15.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
16.

Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.

Rajkhowa M, Neary RH, Kumpatla P, Game FL, Jones PW, Obhrai MS, Clayton RN.

J Clin Endocrinol Metab. 1997 Oct;82(10):3389-94.

PMID:
9329374
17.

Pathogenesis and management of the dyslipidemia of the metabolic syndrome.

Raal FJ.

Metab Syndr Relat Disord. 2009 Apr;7(2):83-8. doi: 10.1089/met.2008.0079. Review.

PMID:
19400742
18.

Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary.

Mark L, Vallejo-Vaz AJ, Reiber I, Paragh G, Kondapally Seshasai SR, Ray KK.

Atherosclerosis. 2015 Jul;241(1):62-8. doi: 10.1016/j.atherosclerosis.2015.04.810. Epub 2015 Apr 30.

PMID:
25966441
19.

[Dyslipidemia and obesity 2011. Similarities and differences].

Ceska R, Vrablík M, Sucharda P.

Vnitr Lek. 2011 Mar;57(3):248-53. Review. Czech.

PMID:
21495405
20.

Diabetic dyslipidemia.

Kreisberg RA.

Am J Cardiol. 1998 Dec 17;82(12A):67U-73U; discussion 85U-86U. Review.

PMID:
9915665

Supplemental Content

Support Center